title: [Evaluation of a combination chemotherapy with docetaxel and nedaplatin for patients with oral squamous cell carcinomas].
abstract: The purpose of this study was to evaluate the effectiveness and safety of combination chemotherapy with docetaxel (TXT) and nedaplatin (CDGP) for patients with oral squamous cell carcinomas. Eight patients were enrolled in this study (4 men and 4 women, with a mean age of 61.7 years). TXT and CDGP were administered at a dose of 60 mg/m(2) and 70 mg/m(2) by drip infusion for 120 minutes, respectively. Three patients received one more administration 4 weeks after the first one. The locoregional response was evaluated 4 weeks after the final administration of TXT and CDGP. As a result, the locoregional response rate after 1 course was 62.5% including 25.0% of complete response (CR). The response rate after 2 courses was 100.0% with 66.7% of CR. According to Oboshi and Shimosato's classification, histological evaluation of surgical specimens revealed that four cases were Grade IIa, two cases Grade IIb, and two cases Grade IV. The severe adverse events were neutropenia and leukopenia, which were effectively managed with granulocyte colony-stimulating factor (G-CSF). No other severe side effects were recognized. The present study suggested that the combination chemotherapy with TXT and CDGP would be an effective and safe regimen in neo-adjuvant chemotherapy for oral squamous cell carcinomas.
authors.affiliation: Division of Dentistry and Oral Surgery, Akita University Hospital.
authors.forename: Kaoru
authors.initials: K
authors.lastname: Yamaoka
authors.forename: Masayuki
authors.initials: M
authors.lastname: Fukuda
authors.forename: Shigetomo
authors.initials: S
authors.lastname: Hatakeyama
authors.forename: Daigo
authors.initials: D
authors.lastname: Murayama
authors.forename: Ryo
authors.initials: R
authors.lastname: Kashiwagi
authors.forename: Tetsusada
authors.initials: T
authors.lastname: Musashi
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Ohnuki
authors.forename: Kotaro
authors.initials: K
authors.lastname: Miyoshi
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nagai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nanjo
authors.forename: Youji
authors.initials: Y
authors.lastname: Miyamoto
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; C053989:nedaplatin